DE69534753D1 - Nierenpolycystose-gen - Google Patents

Nierenpolycystose-gen

Info

Publication number
DE69534753D1
DE69534753D1 DE69534753T DE69534753T DE69534753D1 DE 69534753 D1 DE69534753 D1 DE 69534753D1 DE 69534753 T DE69534753 T DE 69534753T DE 69534753 T DE69534753 T DE 69534753T DE 69534753 D1 DE69534753 D1 DE 69534753D1
Authority
DE
Germany
Prior art keywords
pkd1
gene
cyst formation
compositions
nierenpolycystose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534753T
Other languages
English (en)
Other versions
DE69534753T2 (de
Inventor
W Klinger
M Landes
C Burn
D Connors
William Dackowski
Gregory Germino
Feng Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Johns Hopkins University
Original Assignee
Genzyme Corp
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/323,443 external-priority patent/US5654170A/en
Application filed by Genzyme Corp, Johns Hopkins University filed Critical Genzyme Corp
Application granted granted Critical
Publication of DE69534753D1 publication Critical patent/DE69534753D1/de
Publication of DE69534753T2 publication Critical patent/DE69534753T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE69534753T 1994-10-12 1995-10-11 Nierenpolycystose-gen Expired - Lifetime DE69534753T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US381520 1981-07-10
US323443 1994-10-12
US08/323,443 US5654170A (en) 1994-10-12 1994-10-12 Polycystic kidney disease gene
US38152095A 1995-01-31 1995-01-31
PCT/US1995/013357 WO1996012033A1 (en) 1994-10-12 1995-10-11 Polycystic kidney disease gene

Publications (2)

Publication Number Publication Date
DE69534753D1 true DE69534753D1 (de) 2006-04-06
DE69534753T2 DE69534753T2 (de) 2006-11-02

Family

ID=26983965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534753T Expired - Lifetime DE69534753T2 (de) 1994-10-12 1995-10-11 Nierenpolycystose-gen

Country Status (10)

Country Link
US (1) US6867288B1 (de)
EP (1) EP0782630B1 (de)
AT (1) ATE316136T1 (de)
AU (1) AU706167B2 (de)
CA (1) CA2202283A1 (de)
DE (1) DE69534753T2 (de)
DK (1) DK0782630T3 (de)
ES (1) ES2256851T3 (de)
PT (1) PT782630E (de)
WO (1) WO1996012033A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US6824767B2 (en) * 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
EP0918855A1 (de) * 1996-05-24 1999-06-02 Genzyme Corporation Polyzystisches nierenkrankheitesgen
DE19650758C1 (de) * 1996-12-06 1998-01-02 Deutsches Krebsforsch PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper
US6399349B1 (en) * 1997-09-02 2002-06-04 James W. Ryan Human aminopeptidase P gene
CA2697031C (en) 2000-07-13 2017-10-31 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
CA2993381C (en) 2006-07-24 2020-07-14 Athena Diagnostics, Inc. Method of detecting the occurrence of adpkd based on presence of nucleotide sequence alteration in pkd1
US8424594B2 (en) * 2007-12-10 2013-04-23 Presto Engineering, Inc. Apparatus for thermal control in the analysis of electronic devices
WO2012110999A1 (en) * 2011-02-16 2012-08-23 Compugen Ltd Genetic markers for prognosis of rheumatoid arthritis treatment efficacy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3715314B2 (ja) * 1993-12-24 2005-11-09 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン 結節硬化症2遺伝子及びその利用
EP0777728A1 (de) * 1994-06-14 1997-06-11 Medical Research Council Polyzystisches nierenkrankheits-1-gen und verwendung davon
US6071717A (en) * 1995-01-31 2000-06-06 Genzyme Corporation Polycystic kidney disease gene and protein

Also Published As

Publication number Publication date
JP4495255B2 (ja) 2010-06-30
EP0782630A4 (de) 1997-12-17
ATE316136T1 (de) 2006-02-15
EP0782630B1 (de) 2006-01-18
DK0782630T3 (da) 2006-05-29
EP0782630A1 (de) 1997-07-09
DE69534753T2 (de) 2006-11-02
AU4002795A (en) 1996-05-06
AU706167B2 (en) 1999-06-10
PT782630E (pt) 2006-06-30
ES2256851T3 (es) 2006-07-16
WO1996012033A1 (en) 1996-04-25
CA2202283A1 (en) 1996-04-25
JP2001520502A (ja) 2001-10-30
US6867288B1 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ES2194057T3 (es) Inhibidor de proteasa de leucocitos de secrecion (slpi) como inhibidor de triptasa.
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE69526216T2 (de) Antifungaleverfahren und mitteln
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
UA27035C2 (uk) Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69534753D1 (de) Nierenpolycystose-gen
DE69731463D1 (de) Rekombinante ribonuklease proteine
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
EP0716591A4 (de) Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
PT938329E (pt) Composicao de tlp imunogenica
DE58907373D1 (de) Modifizierte Proteine.
GB9723824D0 (en) Cytostatic agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 782630

Country of ref document: EP

Representative=s name: WESTPHAL, MUSSGNUG & PARTNER, DE